NU680 Unit 6 Genitourinary Syndrome Case Analysis Example

Three Bladder Infections and a Prescription She Was Afraid to Fill: A Unit 6 Case Analysis of Genitourinary Syndrome After Breast Cancer

[Student Name]

Purdue University Global

NU680: Gynecological, Reproductive, and Sexual Health

Unit 6 Genitourinary Syndrome Case Analysis

[Instructor Name]

[Date]

The patient is composite; her values are illustrative; the sources cited are real.

The Case

Ms. Duchesne was diagnosed at 55 with stage I, estrogen receptor positive breast cancer. She had a lumpectomy and radiation and has taken anastrozole, an aromatase inhibitor, for two years, with three to eight years left to go depending on her oncologist's plan. She went through menopause at 51. Since starting anastrozole she has had vaginal dryness and burning, pain with penetration severe enough that the couple stopped having intercourse, and urinary urgency. Over the past twelve months she has had three culture-confirmed bladder infections, each treated with a short antibiotic course.

On examination the vaginal tissue is pale and thin, its folds flattened, with tiny fissures at the entrance of the vagina, which is tender to a cotton swab. The vaginal pH is 6.5. A primary care clinician prescribed vaginal estradiol cream last year, but she never filled it after reading online that estrogen "feeds" breast cancer.

Naming the Condition

Genitourinary syndrome of menopause is the term The North American Menopause Society (NAMS) uses for the group of vaginal, vulvar and urinary changes caused by low estrogen, replacing older terms such as vaginal atrophy (NAMS, 2020). It is chronic and progressive without treatment, unlike hot flashes, which often ease with time. Aromatase inhibitors make it worse because they lower estrogen to very low levels throughout the body, which is how they reduce cancer recurrence. Her urinary urgency and repeated infections are part of the same syndrome, since the urethra and bladder neck also depend on estrogen.

Other Explanations to Exclude

Before attributing everything to the syndrome, the analysis considers other causes. Recurrent infections can come from incomplete emptying, so a post-void residual is measured; it is 40 milliliters, normal. Vulvar pain can come from lichen sclerosus, which causes white, thinned skin and requires a different treatment; her skin does not show those changes. A yeast infection or bacterial vaginosis can cause burning; a wet mount is negative. Radiation was to the breast, not the pelvis, so radiation injury is not a factor.

Ranking the Treatments

Both NAMS and a committee opinion written for survivors by the specialty college for obstetricians (American College of Obstetricians and Gynecologists [ACOG]) lay out a stepwise approach for breast cancer survivors, beginning with treatments that contain no hormones (ACOG, 2016; NAMS, 2020).

Vaginal moisturizers. Applied every two to three days regardless of sexual activity, they rehydrate the tissue and can reduce dryness and burning. Regular use matters more than the brand.

Lubricants. Used during intercourse, silicone-based lubricants last longer than water-based ones and do not contain the irritants some flavored or warming products do.

Topical lidocaine for entry pain. In a randomized trial among breast cancer survivors with severe pain at the vaginal entrance, applying 4 percent aqueous lidocaine to the tissue for three minutes before penetration reduced pain significantly compared with saline, and most participants later reported comfortable intercourse (Goetsch et al., 2015). Her fissures and tenderness at the entrance make this a strong fit.

Pelvic floor physical therapy and dilators. After months of painful intercourse, the pelvic floor muscles often tighten protectively, which adds to the pain. A pelvic floor physical therapist can address this, and vaginal dilators help the tissue tolerate stretching gradually.

For her, the first steps are a moisturizer, a lubricant, lidocaine at the entrance and a referral, none of which needs her oncologist's approval.

The Estrogen Question

If these steps do not give enough relief, low-dose vaginal estrogen is the most effective treatment. The concern for Ms. Duchesne is specific. Vaginal estrogen produces small rises in blood estradiol, and in a woman on an aromatase inhibitor, whose treatment works by keeping estradiol very low, even small rises could in theory reduce the drug's effect. ACOG (2016) recommends that vaginal estrogen in women with a history of estrogen-dependent breast cancer be reserved for those whose symptoms do not respond to nonhormonal approaches, and that the decision be made with the patient's oncologist. NAMS (2020) notes that data on recurrence risk are limited and reassuring but that the aromatase inhibitor setting deserves particular caution.

The analysis therefore does not tell her to fill the old prescription. It tells her that the online claim was too simple, that estrogen is a reasonable option if other treatments fail, and that it would be her oncologist's decision as much as hers. If the oncologist agrees, the lowest dose, such as a 10-microgram estradiol vaginal tablet twice weekly after an initial two weeks of nightly use, would be chosen. Some oncologists prefer switching to tamoxifen, which affects the vagina differently, if vaginal estrogen becomes necessary.

Preventing the Infections

Three infections in a year meets the usual definition of recurrent infection. Vaginal estrogen reduces recurrent infections in postmenopausal women, but while that decision is pending she needs another option. Daily low-dose antibiotic prophylaxis works but risks resistance and side effects. In a randomized noninferiority trial, methenamine hippurate, a urinary antiseptic that is not an antibiotic, prevented recurrent infections about as well as daily antibiotics in women with recurrent infections (Harding et al., 2022). Methenamine hippurate 1 gram twice daily is offered, with a check of kidney function first and advice to avoid taking it with urinary alkalinizers.

The Plan

The plan has five parts. She starts a moisturizer three times a week and uses a silicone lubricant during intercourse. She receives a prescription for 4 percent aqueous lidocaine with instructions to apply it with a cotton ball to the entrance for three minutes before penetration and then remove excess. She is referred to a pelvic floor physical therapist. She starts methenamine hippurate. And a message, sent with her permission, asks her oncologist about vaginal estrogen if symptoms persist after three months.

Follow-Up

She returns in three months. The visit will ask about pain with intercourse on a 0 to 10 scale, dryness, urgency and any new infections, and will repeat the vaginal pH. If pain remains above 4 despite the nonhormonal steps, the estrogen discussion with the oncologist will move forward. A new lump, bone pain or vaginal bleeding would prompt an urgent visit.

Conclusion

Ms. Duchesne's symptoms are common, treatable and closely tied to the medicine that protects her from recurrence. The analysis begins with treatments that do not involve hormones, adds a nonantibiotic way to prevent infections, and treats vaginal estrogen as a decision to be made with her oncologist rather than either a forbidden drug or a routine prescription.

References

American College of Obstetricians and Gynecologists. (2016). Committee opinion no. 659: The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstetrics & Gynecology, 127(3), e93-e96. https://doi.org/10.1097/AOG.0000000000001351

Goetsch, M. F., Lim, J. Y., & Caughey, A. B. (2015). A practical solution for dyspareunia in breast cancer survivors: A randomized controlled trial. Journal of Clinical Oncology, 33(30), 3394-3400. https://doi.org/10.1200/JCO.2014.60.7366

Harding, C., Mossop, H., Homer, T., Chadwick, T., King, W., Carnell, S., Lecouturier, J., Abouhajar, A., Vale, L., Watson, G., Forbes, R., Currer, S., Pickard, R., Eardley, I., Pearce, I., Thiruchelvam, N., Guerrero, K., Walton, K., Hussain, Z., Lazarowicz, H., & Ali, A. (2022). Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: Multicentre, open label, randomised, non-inferiority trial. BMJ, 376, e068229. https://doi.org/10.1136/bmj-2021-0068229

North American Menopause Society. (2020). The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause, 27(9), 976-992. https://doi.org/10.1097/GME.0000000000001609